Cytek Biosciences, Inc. (CTKB) Revenue by Segment & Business Profile
Product was 67.6% of Cytek Biosciences, Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTKBCytek Biosciences, Inc.Follow CTKB — free
—
Price chart with a free account
- Market cap
- 726.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What the company does
Cytek Biosciences, Inc. is a medical devices company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (68%), Service (32%). Trailing twelve-month revenue: $206.7 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Diagnostics / life-science tools
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 28M | 58.6% | +18.1% |
| EMEA | 11M | 23.5% | -8.2% |
| Asia Pacific | 8M | 16.4% | +0.6% |
| Other | 1M | 1.5% | -54.2% |
Cytek Biosciences, Inc. — questions
- What does Cytek Biosciences, Inc. do?
- Cytek Biosciences, Inc. is a medical devices company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (68%), Service (32%). Trailing twelve-month revenue: $206.7 million as of 2026-06-30.
- How does Cytek Biosciences, Inc. make money?
- By the lines it reports in its SEC filings: Product 67.6%, Service 32.4% of revenue.
Every figure on this page comes from Cytek Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.